Hyperkalemia in the Patient Receiving Specialized Nutrition Support

Journal of Parenteral and Enteral Nutrition

Volumn 28, Issue 2, 2004, Pages 124-127

  Dickerson, Roland N ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMILORIDE; AMINOCAPROIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HEPARIN; IBUPROFEN; INDOMETACIN; LISINOPRIL; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PENICILLIN G POTASSIUM; PENTAMIDINE; PHENYLEPHRINE; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; PROPRANOLOL; SPIRONOLACTONE; TACROLIMUS; TRIAMTERENE; TRIMETHOPRIM;

ACIDOSIS; AGE; ARTERIAL PH; DIABETES MELLITUS; DISEASE PREDISPOSITION; EDITORIAL; ELECTROCARDIOGRAM; HEMOLYSIS; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; LEUKOCYTOSIS; NUTRITIONAL SUPPORT; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PRIORITY JOURNAL;

EID: 1642313705     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607104028002124     Document Type: Editorial

References (50)

1. Rivard AL, Raup SM, Beilman GJ. Sodium polystyrene sulfonate used to reduce the potassium content of a high protein enteral formula: a quantitative analysis. JPEN. 2004;28:76-78.
2. Vanlandingham S, Simpson S, Daniel P, Newmark SR. Metabolic abnormalities in patients supported with enteral tube feeding. JPEN. 1981;5:322-3244.
3. Wiederkehr MR, Moe OW. Factitious hyperkalemia. Am J Kidney Dis. 2000;36:1049-1053.
4. Graber M, Subramani K, Corish D, Schwab A. Thrombocytosis elevates serum potassium. Am J Kidney Dis. 1988;12:116-120.
5. Webster A, Brady W, Morris F. Recognising signs of danger: ECG changes resulting from an abnormal serum potassium concentration. Emerg Med J. 2002;19:74-77.
6. Burnell JM, Villamil MF, Uyeno BT. Effect in humans of extra-cellular pH change in relationship between serum potassium concentration and intracellular potassium. J Clin Invest. 1956; 35:935-939.
7. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. Arch Intern Med. 1998;158:917-924.
8. Riccardella D, Dwyer J. Salt substitutes and medicinal potassium sources: risks and benefits. J Am Diet Assoc. 1985;85:471-474.
9. Mercer CW, Logic JR. Cardiac arrest due to hyperkalemia following intravenous penicillin administration. Chest. 1973;64: 358-359.
10. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med. 2000;109:307-314.
11. Hoye A, Clark A. Iatrogenic hyperkalaemia. Lancet. 2003;361: 2124.
12. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
13. Mulkerrin E, Epstein FH, Clark BA. Aldosterone responses to hyperkalemia in healthy elderly humans. J Am Soc Nephrol. 1995;6:1459-1462.
14. Biswas K, Mulkerrin EC. Potassium homoeostasis in the elderly. QJM. 1997;90:487-492.
15. Perazella MA. Trimethoprim is a potassium-sparing diuretic like amiloride and causes hyperkalemia in high-risk patients. Am J Ther. 1997;4:343-348.
16. Luckey AE, Parsa CJ. Fluid and electrolytes in the aged. Arch Surg. 2003;138:1055-1060.
17. Mayan H, Kantor R, Farfel Z. Trans-tubular potassium gradient in patients with drug-induced hyperkalemia. Nephron. 2001;89: 56-61.
18. Perez GO, Lespier L, Knowles R, Vaamonde CA. Potassium homeostasis in chronic diabetes mellitus. Arch Intern Med. 1977; 137:1018-1022.
19. DeFronzo RA. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int. 1980;17:118-134.
20. Goldfarb S, Cox M, Singer I, Goldberg M. Acute hyperkalemia induced by hyperglycemia: hormonal mechanisms. Ann Intern Med. 1976;84:426-432.
21. Nanji AA. Drug-induced electrolyte disorders. Drug Intell Clin Pharm. 1983;17:175-185.
22. Brass EP, Thompson WL. Drug-induced electrolyte abnormalities. Drugs. 1982;24:207-228.
23. Rimmer JM, Horn JF, Gennari FJ. Hyperkalemia as a complication of drug therapy. Arch Intern Med. 1987;147:867-869.
24. Moore ML, Bailey RR. Hyperkalaemia in patients in hospital. N Z Med J. 1989;102:557-558.
25. Hu Y, Carpenter JP, Cheung AT. Life-threatening hyperkalemia: a coniplication of spironolactone for heart failure in a patient with renal insufficiency. Anesth Analg. 2002;95:39-41.
26. Tan SY, Shapiro R, Franco R, Stockard H, Mulrow PJ. Indomethacin-induced prostaglandin inhibition with hyperkalemia: a reversible cause of hyporeninemic hypoaldosteronism. Ann Intern Med. 1979;90:783-785.
27. Zimran A, Kramer M, Plaskin M, Hershko C. Incidence of hyperkalaemia induced by indomethacin in a hospital population. BMJ. 1985;291:107-108.
28. Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 1995;98:575-586.
29. Busch EH, Ventura HO, Lavie CJ. Heparin-induced hyperkalemia. South Med J. 1987;80:1450-1451.
30. Orlando MP, Dillon ME, O'Dell MW. Heparin-induced hyperkalemia confirmed by drug rechallenge. Am J Phys Med Rehabil. 2000;79:93-96.
31. Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med. 1993;119;291-295.
32. Velazquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119:296-301.
33. Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med. 1996;124:316-320.
34. Marinella MA. Trimethoprim-induced hyperkalemia: an analysis of reported cases. Gerontology. 1999;45:209-212.
35. Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clin Nephrol. 1996;46:187-192.
36. Lachaal M, Venuto RC. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med. 1989;87:260-263.
37. Sargent AI, Overton CC, Kuwik RJ, Varcelotti JR, Deppe SA. Octreotide-induced hyperkalemia. Pharmacotherapy. 1994;14: 497-501.
38. Brown RO, Hamrick KD, Dickerson RN, Lee N, Parnell DH Jr, Kudsk KA. Hyperkalemia secondary to concurrent pharmacotherapy in a patient receiving home parenteral nutrition. JPEN. 1996;20:429-432.
39. Berglund G, Andersson O, Larsson O, Wilhelmsen L. Antihypertensive effect and side-effects of bendroflumethiazide and propranolol. Acta Med Scand. 1976;199:499-506.
40. Woo M, Przepiorka D, Ippoliti C, et al. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Bone Marrow Transplant. 1997;20:1095-1098.
41. Kamel KS, Ethier JH, Quaggin S, et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. J Am Soc Nephrol. 1992;2:1279-1284.
42. Williams ME, Rosa RM, Silva P, Brown RS, Epstein FH. Impairment of extrarenal potassium disposal by alpha-adrenergic stimulation. N Engl J Med. 1984;311:145-149.
43. Perazella MA, Biswas P. Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy. Am J Kidney Dis. 1999;33:782-785.
44. Schepkens H, Vanholder R, Billiouw JM, et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438-441.
45. Hay E, Derazon H, Bukish N, Katz L, Kruglyakov I, Armoni M. Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. J Emerg Med. 2002;22:349-352.
46. Fagerman KE. Limiting bacterial contamination of enteral nutrient solutions: 6-year history with reduction of contamination at two institutions. Nutr Clin Pract. 1992;7:31-36.
47. Fagerman KE, Paauw JD, McCamish MA, Dean RE. Effects of time, temperature, and preservative on bacterial growth in enteral nutrient solutions. Am J Hosp Pharm. 1984;41:1122-1126.
48. Paauw JD, Fagerman KE, McCamish MA, Dean RE. Enteral nutrient solutions: limiting bacterial growth. Am Surg. 1984;50: 312-316.
49. de Leeuw IH, Vandewoude MF. Bacterial contamination of enteral diets. Gut. 1986;27(Suppl 1):56-57.
50. McCowen KC, Bistrian BR. Immunonutrition: problematic or problem solving? Am J Clin Nutr. 2003;77:764-770.